Homocysteine levels in women with a history of gestational diabetes mellitus

Diabetology & Metabolic Syndrome

Lilianna Majkowska²  Krzysztof Safranow¹  Aneta Fronczyk²  Piotr Molęda² 

[1] Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstancow Wielkopolskich Av. 72, Szczecin, 71-899, Poland;Department of Diabetology and Internal Medicine, Pomeranian Medical University in Szczecin, Siedlecka 2 Str, Police, 72-010, Poland

关键词: Previous gestational diabetes;    Insulin resistance;    Homocysteine;    Glucose intolerance;   

Others  :  1229622
DOI  :  10.1186/s13098-015-0088-2

 received in 2015-06-16, accepted in 2015-10-14,  发布年份 2015

【 摘 要 】

Background

Previous gestational diabetes (pGDM) is a risk factor of type 2 diabetes, hypertension and cardiovascular diseases. Homocysteine is one of markers of cardiovascular risk. The aim of this study was to assess the homocysteine levels in women with pGDM and to evaluate its relationship with current carbohydrate metabolism and nourishment status.

Methods

The study group comprised 199 women at 7.8 ± 1.0 years after pGDM and 50 control women in whom pGDM was excluded. The analyzed parameters: BMI, WHR, body composition (Tanita SC-330S analyzer), glucose and insulin levels in oral glucose tolerance test (OGTT), insulin resistance index (HOMA-IR), HbA1c, lipid profile, homocysteine, creatinine and creatinine clearance. The Mann–Whitney test and Chi–squared test were used for comparison of continuous and nominal variables, respectively. Correlations between continuous variables in each group were analyzed using Spearman’s rank correlation coefficient (Rs). A logarithmic transformation was applied for variables with non-normal distribution.

Results

There were no differences between the pGDM women and controls in terms of age, number of childbirths, time from indexed pregnancy, pre-pregnancy BMI, or current anthropometric parameters. In pGDM women HbA1c and all glucose levels in OGTT were significantly higher, but still within the normal range. No significant differences were found in homocysteine levels, HOMA-IR, blood lipids, creatinine and creatinine clearance. Homocysteine levels did not differ significantly in subgroups categorized according to the current OGTT results or BMI. Carbohydrate metabolism disorders, overweight and obesity were associated with higher creatinine clearance. Positive correlation between homocysteine and creatinine (r = 0.21, p < 0.004), and a negative correlation with creatinine clearance (r = −0.16, p < 0.03) were found.

Conclusions

In women with pGDM, homocysteine is not a marker of glucose tolerance disturbances and cardiovascular risk. Increased glomerular filtration rate, observed in more severe disorders of carbohydrate metabolism and greater BMI, may temporarily protect against an increase of proatherogenic homocysteine.

【 授权许可】

   
2015 Molęda et al.

【 参考文献 】

• [1]Feig DS, Zinman B, Wang X, Hux JE: Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ 2008, 179:229-234.
• [2]Davis CL, Gutt M, Llabre MM, Marks JB, O’Sullivan MJ, Potter JE, et al.: History of gestational diabetes, insulin resistance and coronary risk. J Diabetes Complicat 1999, 13:216-223.
• [3]Lind JM, Hennessy A, McLean M: Cardiovascular disease in women: the significance of hypertension and gestational diabetes during pregnancy. Curr Opin Cardiol 2014, 29:447-453.
• [4]Bellamy L, Casas JP, Hingorani AD, Williams D: Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009, 373:1773-1779.
• [5]Catalano PM: Carbohydrate metabolism and gestational diabetes. Clin Obstet Gynecol 1994, 37:25-38.
• [6]Atay AE, Simsek H, Demir B, Sakar MN, Kaya M, Pasa S, et al.: Noninvasive assessment of subclinical atherosclerosis in normotensive gravidae with gestational diabetes. Herz 2014, 39:627-632.
• [7]López-Tinoco C, Roca M, Fernández-Deudero A, García-Valero A, Bugatto F, Aguilar-Diosdado M, Bartha JL: Cytokine profile, metabolic syndrome and cardiovascular disease risk in women with late-onset gestational diabetes mellitus. Cytokine 2012, 58:14-19.
• [8]Schalinske KL, Smazal AL: Homocysteine Imbalance: a pathological metabolic marker. Adv Nutr 2012, 3:755-762.
• [9]Pushpakumar S, Kundu S, Sen U: Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem 2014, 21:3662-3672.
• [10]Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al.: Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998, 80:566-569.
• [11]Hoffman MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al.: Hyperhomocysteinaemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Intern Med 2000, 247:675-683.
• [12]Zeng X, Dai J, Remick DG, Wang X: Homocysteine-mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res 2003, 93:311-320.
• [13]Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, et al.: Framingham offspring study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001, 24:1403-1410.
• [14]Catena C, Colussi G, Nait F, Capobianco F, Sechi LA: Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients. Am J Hypertens 2014.
• [15]Asemi Z, Karamali M, Esmaillzadeh A: Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Mol Nutr Food Res 2014, 58:1465-1473.
• [16]Vitoratos N, Kassanos D, Salamalekis E, Siristatidis Ch, Baimacou E, Creatsas G: Maternal homocysteine levels and plasma lipids in gestational diabetes: is there any relationship? J Obstet Gynaecol 2002, 22:366-369.
• [17]Idzior-Waluś B, Cyganek K, Sztefko K, Seghieri G, Breschi MC, Waluś-Miarka M, et al.: Total plasma homocysteine correlates in women with gestational diabetes. Arch Gynecol Obstet 2008, 278:309-313.
• [18]Guven MA, Cetinkaya A: Elevated plasma homocysteine levels in gestational diabetes mellitus. Acta Obstet Gynecol Scand 2005, 84:306-307.
• [19]Cho NH, Lim S, Jang HC, Park HK, Metzger BE: Elevated homocysteine as a risk factor for the development of diabetes in women with a previous history of gestational diabetes mellitus: a 4-year prospective study. Diabetes Care 2005, 28:2750-2755.
• [20]Alatab S, Fakhrzadeh H, Sharifi F, Mirarefin M, Badamchizadeh Z, Ghaderpanahi M, et al.: Correlation of serum homocysteine and previous history of gestational diabetes mellitus. J Diabetes Metab Disord 2013, 12:34. BioMed Central Full Text
• [21]http://www.dtu.ox.ac.uk/index.php?maindoc=/homa/index.php. Accessed 30 Dec 2013.
• [22]Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: queryreport of a WHO/IDF consultation. Geneva: World Health Organization; 2006. p. 13–33.
• [23]Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes. A systematic review. Diabetes Care 2002, 25:1862-1868.
• [24]Munshi MN, Stone A, Fink L, Fonseca V: Hyperhomocysteinemia following a methionine load in patients with noninsulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996, 45:133-135.
• [25]Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al.: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998, 98:204-210.
• [26]Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA, et al.: Fasting and postmethionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999, 22:125-132.
• [27]Schäfer SA, Müssig K, Stefan N, Häring HU, Fritsche A, Balletshofer BM: Plasma homocysteine concentrations in young individuals at increased risk of type 2 diabetes are associated with subtle differences in glomerular filtration rate but not with insulin resistance. Exp Clin Endocrinol Diabetes 2006, 114:306-309.
• [28]Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D: Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants. Kidney Blood Press Res 2008, 31:259-267.
• [29]Bosma RJ, van der Heide JJ, Oosterop EJ, de Jong PE, Navis G: Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004, 65:259-265.
• [30]Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP: Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000, 23:1816-1822.
• [31]Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-138.
• [32]Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J: Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol 2014, 9:167. BioMed Central Full Text